Arca Biopharma Inc., of Westminster, Colo., said the data and safety monitoring board for the GENETIC-AF trial completed its pre-specified phase IIb interim analysis and recommended completion of the trial with no changes. GENETIC-AF is evaluating beta-blocker Gencaro (bucindolol hydrochloride) as a potential treatment for atrial fibrillation. Top-line results are expected late in the first quarter of 2018. The Gencaro development program has been granted fast track designation by the FDA.